General Information of Drug (ID: DMDPNCJ)

Drug Name
IMO-8400 Drug Info
Synonyms Bazlitoran; Bazlitoran [INN]; Bazlitoran [USAN]; UNII-2U46M95B5M; 2U46M95B5M
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Phase 2 [1]
Diffuse large B-cell lymphoma 2A81 Phase 1/2 [2]
Waldenstrom macroglobulinemia 2A85.4 Phase 1/2 [2]
Cross-matching ID
PubChem CID
119058029
CAS Number
CAS 1378549-07-5
TTD Drug ID
DMDPNCJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting Toll-like receptor (TLR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DPV-001 DMMC3XR Non-small-cell lung cancer 2C25.Y Phase 2 [3]
BDB001 DMKFJXP Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
IMO-9200 DMEHWPC Autoimmune disease 4A40-4A45 Phase 1 [1]
PMID30280939-Compound-WO2009082440 DMXRHCJ N. A. N. A. Patented [5]
PMID30280939-Compound-US20179642901 DMPVW2Q Malaria 1F40-1F45 Patented [5]
PMID30280939-Compound-WO2015150568 DMGCE3Z N. A. N. A. Patented [5]
PMID30280939-Compound-WO200606195 DMLVSEK N. A. N. A. Patented [5]
PMID30280939-Compound-WO2005070959 DM6VP5K N. A. N. A. Patented [5]
PMID30280939-Compound-WO2013148426 DMUKIEJ Malaria 1F40-1F45 Patented [5]
PMID30280939-Compound-WO2013148427 DM4Z2KY N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor (TLR) TTOK0LR NOUNIPROTAC Antagonist [2]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 UbiVac's DRibble, autophagosome-enriched vaccines: Applications for cancer and infectious disease. UbiVac. 2013.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.